GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans

Hypertension. 2021 Sep;78(4):1092-1102. doi: 10.1161/HYPERTENSIONAHA.121.17659. Epub 2021 Aug 30.

¹ Department of Medicine, Division of Clinical Pharmacology (J.M.L., D.W., A.D., R.M., D.P., J.G., N.J.B.), Vanderbilt University Medical Center.
² Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY (J.R.).
³ Department of Medicine, Division of Infectious Diseases (J.R.K., L.H.), Vanderbilt University Medical Center.
⁴ Department of Medicine, Division of Nephrology and Hypertension (A.S.T.), Vanderbilt University Medical Center.
⁵ Department of Biostatistics (H.N., C.Y.), Vanderbilt University Medical Center.
⁶ Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism (M.M.), Vanderbilt University Medical Center.
⁷ Yale School of Medicine (N.J.B.).

Abstract

[Figure: see text].

Keywords: eicosanoids; epoxide hydrolases; hypertension; insulin resistance; oxidative stress.

Cyclohexylamines
F2-Isoprostanes
N-((4-cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide
Triazines
Epoxide Hydrolases